Precision BioSciences (NASDAQ:DTIL) saw its stock rise 5% following the announcement that the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation to its PBGENE-DMD therapy for ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Precision BioSciences is also currently evaluating PBGENE-PMM, a first-of-its-kind treatment for m.3243 associated mitochondrial disease, in pre-clinical studies.

Precision BioSciences shares are trading higher Tuesday after the company announced a licensing agreement with TG Therapeutics, Inc. Precision will receive $17.5 million in upfront and near-term ...

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other ...

- Wholly owned programs on track for CTA and/or IND submissions - PBGENE-HBV for Hepatitis B virus in 2024 and PBGENE-PMM for primary mitochondrial myopathy in 2025 “In 2024, Precision is ...

- Company to expand its Phase 1 ELIMINATE-B study to the U.S., joining world-class clinical sites in Moldova, Hong Kong, and New Zealand where strong clinical execution is currently underway ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $60.00. Patrick Trucchio’s rating is based on ...

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other ...

BGENE-DMD is designed to treat Duchenne muscular dystrophy (DMD) via a one-time administration in a single AAV.

Investing.com -- Precision BioSciences (NASDAQ: DTIL) stock rose 5% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its PBGENE-DMD ...